Glenmark Life Sciences Limited

About the company

About Glenmark Life Sciences Incorporated in 2011, Glenmark Life Sciences is a wholly-owned subsidiary of Glenmark Pharmaceuticals. It is a leading developer and manufacturer of active pharmaceutical ingredients (API) in chronic therapeutic areas including cardiovascular disease, central nervous system disease, pain management and diabetes. The company’s key business vertical is generic API, which contributes around 91% of the revenue. The remaining 9% of the revenue includes 8% from contract development and manufacturing operations (CDMO) to multinational and specialty pharma companies and 1% from other operating income. Headquartered in India, Glenmark Life Sciences has a diversified portfolio of products and customers. The company has developed 120 molecules, which it sells in India, Europe, Latin America, North America, Japan and the rest of the world. Of the 20 largest generic pharma companies in the world, 16 are customers of Glenmark Life Sciences. This has helped the company deliver strong financial performance over the years. The company’s revenue and net profit have grown at a CAGR of 45% and 34%, respectively, during FY19–21.

Financial performance (₹ Cr)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   27 Jul 2021

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   29 Jul 2021

   Last day to place your bid

3. Basis of Allotment

   Completed
   29 Jul 2021

   Share allotment finalised

4. Refund Initiation

   Completed
   04 Aug 2021

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   03 Aug 2021

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   06 Aug 2021

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.